Login / Signup

Juvenile-onset myopia-who to treat and how to evaluate success.

Mark A BullimoreNoel A Brennan
Published in: Eye (London, England) (2023)
The risk of eye diseases such as myopic macular degeneration increases with the level of myopia, but there is no safe level of myopia and the burden of lower degrees of myopia remains considerable. Effective treatments are available that slow progression and thus limit the final degree of myopia. In this review, the rationale for slowing progression is summarized, and a case made for treating all myopic children. Measurement of refractive error and axial length is reviewed, stressing the precision of optical biometry, but also the need for cycloplegic autorefraction. The factors influencing progression are considered and the available tools for interpretation of progression rate are discussed. Finally, the need to set attainable treatment goals is emphasized.
Keyphrases
  • optic nerve
  • young adults
  • clinical trial
  • diabetic retinopathy
  • high speed
  • smoking cessation